After an infection, experts give advice on how to use eye creams correctly.

Published Date: 08 Mar 2023

Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.

Read Full News

Latest News

What Caused the Pigmented Spot on Teen Boy's Eye?

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

The HCPFive: Top News for Healthcare Providers from the Week of 01/25 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

News All Time

Consider This Before Cataract Surgery; Grant Rule: What's Next? CDC Nominee Grilled

MedPage Today reporters offer further insights into recently covered topics

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Similar results in patients who had port delivery system for 4 years or switched after 64 weeks

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 years

Drugs for Dry AMD Linked to Thickening of Retinal Nerve

More questions than answers, including whether the thickening is neuroprotective or pathologic

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

Branded Bevacizumab Approved for Wet AMD

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor

Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

Findings add to existing evidence linking the drug class to ophthalmic conditions

Medicare's Paying Less for Cataract Surgery. Ophthalmologists Are Turning to Lasers.

— Doctors typically charge $1,000 to $3,000 per eye for use of the laser

Medicare Is Paying Less for Cataract Surgery

Medicare pays doctors about $520 for a standard cataract procedure, down about 20% in the past decade.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

Massage Matches Clinic Probing for Infant Tear Duct Blockage

Gently massaging the tear sacs of infants with blocked tear ducts may be as effective as clinic-based probing for clearing tearing and discharge, a noninferiority trial finds.

Can Dexamethasone Drops Prevent Retinal Disease in Preemies?

Dexamethasone eye drops administered in premature infants with early-stage retinal disease appear to reduce the odds of progression to treatment-requiring disease.

Urinary Drug Tadalafil Linked to Glaucoma Risk

Men taking tadalafil for lower urinary tract symptoms face a 22% higher risk of developing glaucoma than those who do not take the drug, a new study finds.

Study Links Uveitis to Higher Risk for Psychiatric Illness

Noninfectious uveitis is linked to higher rates of psychiatric comorbidities, with Black patients most affected, a new study finds.

Recommended News For You

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Risk of a second cancer after early breast cancer is low, say new findings

GLP-1 receptor agonists show anti-cancer benefits beyond weight loss

Decrease seen in in situ breast cancer since 2009

Researchers find distinct cell receptors with the potential for new treatments.

Pollution exposure may affect lung cancer in women who have never smoked

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

Recommended Articles For You

Spatial Clonal Architecture Genomics in Solid Tumor Evolution 

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies 

Integrated Trends in Hematology for Modern Medicine 

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scholastic performance is a key concern for young cancer patients, study finds

2.

Laser Therapy Shows Promise for Brain Tumors

3.

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

4.

Only 1 in 4 Eligible Adults Receive Lung Screening

5.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

1.

Case Study: The Role of Machine Learning in the Detection of Skin Cancer

2.

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy

3.

Coagulation Factor Consumption During Severe Inflammation: Mechanisms, Clinical Implications, and Advances

4.

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment

5.

Iron Chelation Therapy: Preventing Long-Term Treatment Toxicities

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

3.

Hands-on Workshop: Hematology

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

5.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot